• NL close
• CN close
• SG close
• SE close
• EU close
• Thematic: No close

FerrDb V2 contains 1001 ferroptosis regulators and 143 ferroptosis-disease associations manually curated from 3288 articles. Specifically, there are 621 gene regulators, of which 264 are drivers, 238 are suppressors, 9 are markers, and 110 are unclassified genes; and there are 380 substance regulators, with 201 inducers and 179 inhibitors. Compared to FerrDb V1, curated articles increase by > 300%, ferroptosis regulators increase by 175%, and ferroptosis-disease associations increase by 50.5%. Circular RNA and pseudogene are novel regulators in FerrDb V2, and the percentage of non-coding RNA increases from 7.3% to 13.6%. External gene-related data were integrated, enabling thought-provoking and gene-oriented analysis in FerrDb V2.

European Spallation Source (ESS) Data Catalogue, SciCat instance

The CESSDA Data Catalogue contains the metadata of all data in the holdings of CESSDA service providers. It is a one-stop-shop for search and discovery, enabling effective access to European research data for researchers. Details of over 40, 000 data collections are listed. These are harvested from fifteen different CESSDA Service Providers.

The EPSA | ERNICA Registry is to improve the quality of patient care by enabling health care providers to get insight in their outcomes and using the cumulative data from the EPSA registry to conduct scientific research, for example to compare treatments or identify certain risk factors for complications. The EPSA (European Pediatric Surgical Audit) registry contains information on diseases seen in new-born children, like: Hirschsprung’s disease, Congenital Diaphragmatic Hernia, Oesophageal Atresia, Anorectal Malformation, Omphalocele and Gastroschisis. ERNICA is the European Reference Network for rare Inherited and Congenital (digestive and gastrointestinal) Anomalies European Reference Networks and aims to pool together disease-specific expertise, knowledge and resources from across Europe to achieve health goals that may otherwise be unachievable in a single country. ERNICA monitors and evaluates its activities in accordance with the ERN-wide monitoring framework of expert healthcare professionals from specialised healthcare providers across Europe. These networks seek to pool together the expertise available across Europe and concentrate knowledge and resources on rare and/or complex diseases. Each ERN focuses on a particular rare disease area with two diagnostic groups: Malformations of the digestive system (oesophageal diseases, intestinal diseases, intestinal failure and gastroenterological diseases) and Malformations of the diaphragm and abdominal wall (Malformations of the diaphragm and Abdominal wall defects) This standard defines the metadata required to insure availability, versioning and interoperability of the EPSA|ERNICA data.

NSSDC is the nation-level space science center which recognized by the Ministry of Science and Technology of China. As a repository for space science data, NSSDC assumes the responsibility of the long-term stewardship and offering a reliable service of space science data in China. It also has been the Chinese center for space science of the World Data Center (WDC) since 1988. In 2013, NSSDC became a regular member of World Data System. Data resources are concentrated in the following fields of space physics and space environment, space astronomy, lunar and planetary science, space application and engineering. In space physics, the NSSDC maintains space-based observation data and ground-based observation data of the middle and upper atmosphere, ionosphere and earth surface, from Geo-space Double Star Exploration Program and Meridian Project. In space astronomy, NSSDC archived pointed observation data of Hard X-ray Modulation Telescope. In lunar and planetary science, space application and engineering, NSSDC also collects detection data of Chang’E from Lunar Exploration Program and science products of BeiDou satellites.

Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.